贝达药业出资5000万元投资知兴制药

Core Viewpoint - Beida Pharmaceutical has completed a share transfer agreement with Garden Group, acquiring a 20% stake in Hangzhou Zhixing Pharmaceutical for 50 million yuan, aiming to enhance its position in the biopharmaceutical sector and strengthen its ecosystem in high-barrier technology areas [1] Group 1 - Beida Pharmaceutical's investment in Hangzhou Zhixing Pharmaceutical is part of its strategy to leverage its advantages in the biopharmaceutical field [1] - The company aims to continuously improve its ecosystem layout around high-barrier technology [1] - The acquisition involves a total registered capital of 200 million yuan for Zhixing Pharmaceutical, indicating a significant commitment to the partnership [1] Group 2 - Hangzhou Zhixing Pharmaceutical specializes in the development of high-end inhalation formulations [1] - The core technical team of Zhixing Pharmaceutical has a strong industry background, which is crucial for its operations [1] - Zhixing Pharmaceutical has established a comprehensive research and production system, demonstrating its capability to transition products from laboratory to industrialization [1]